Press releases
- Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
- Calliditas Therapeutics' 2023 Annual Report Published
- Calliditas Announces Positive NefIgArd Open Label Extension Results
- Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
- Calliditas Therapeutics to Attend Conferences in April
- Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
- Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
- Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
- Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
- Calliditas Therapeutics to Attend Investor Conferences in March
More ▼
Key statistics
On Monday, Calliditas Therapeutics AB (LC8A:MUN) closed at 17.60, 18.12% above the 52 week low of 14.90 set on Jul 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.60 |
---|---|
High | 17.60 |
Low | 17.60 |
Bid | 17.50 |
Offer | 19.20 |
Previous close | 17.60 |
Average volume | 0.00 |
---|---|
Shares outstanding | 29.79m |
Free float | 24.79m |
P/E (TTM) | -- |
Market cap | 584.29m USD |
EPS (TTM) | -1.61 USD |
Data delayed at least 15 minutes, as of May 06 2024 07:02 BST.
More ▼